Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case-control and exploratory study.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
02 02 2022
Historique:
received: 05 01 2021
revised: 02 04 2021
pubmed: 10 4 2021
medline: 11 3 2022
entrez: 9 4 2021
Statut: ppublish

Résumé

GCA is a large vessel vasculitis for which triggering factors remain unknown. Clonal haematopoiesis (CH) was associated with atherosclerosis through the induction of inflammation in myeloid cells, and data suggest that CH expansion and inflammation may support each other to induce a pro-inflammatory loop. Our objective was to describe the impact of JAK2p.V617F-mutated myeloproliferative neoplasms (MPNs) on GCA and to screen MPN-free patients for CH mutations. We performed a retrospective case-control study comparing the characteristics of 21 GCA patients with MPN and 42 age- and gender-matched GCA patients without MPN. Also, 18 GCA patients were screened for CH through next-generation sequencing (NGS). The most frequent associated MPN was essential thrombocythaemia (ET; n = 11). Compared with controls, GCA patients with MPN had less-frequent cephalic symptoms (71.4 vs 97.6%; P = 0.004) and higher platelet counts at baseline [485 × 109/l (interquartile range 346-586) vs 346 (296-418); P = 0.02]. There was no difference between groups for other clinical features. Overall survival was significantly shorter in patients with MPN compared with controls [hazard ratio 8.2 (95% CI 1.2, 56.6); P = 0.03]. Finally, screening for CH using NGS in 15 GCA patients without MPN revealed CH in 33%. GCA patients with MPN display higher platelet counts and shorter overall survival than controls. This association is not fortuitous, given the possible pathophysiological relationship between the two diseases. CH was found in one-third of GCA patients, which may be higher than the expected prevalence for a similar age, and should be confirmed in a larger cohort.

Identifiants

pubmed: 33836046
pii: 6219309
doi: 10.1093/rheumatology/keab337
doi:

Substances chimiques

JAK2 protein, human EC 2.7.10.2
Janus Kinase 2 EC 2.7.10.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

775-780

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Matthias Papo (M)

Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases.

Chloé Friedrich (C)

Laboratory of Hematology, Cochin Institute, Paris University, Paris.

Laure Delaval (L)

Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases.

Hubert de Boysson (H)

Department of Internal Medicine, UNICAEN, EA4650 SEILIRM, Caen Normandie University Hospital, Caen.

Jean-François Viallard (JF)

Department of Internal Medicine and Infectious Diseases, Haut Lévêque University Hospital, Bordeaux University, Pessac.

Claude Bachmeyer (C)

Department of Internal Medicine, AP-HP, Tenon Hospital, Sorbonne University.

Thomas Sené (T)

Department of Internal Medicine, Rothschild Foundation Hospital, Paris.

Sébastien Humbert (S)

Internal Medicine Department, University Hospital Besancon, Besançon.

Pierre Duffau (P)

Department of Internal Medicine and Clinical Immunology, Saint Andre Hospital, University Hospital Centre of Bordeaux.
CNRS UMR 5164, Immuno ConcEpT, Bordeaux University, Bordeaux.

Anne Contis (A)

Department of Internal Medicine and Clinical Immunology, Saint Andre Hospital, University Hospital Centre of Bordeaux.
CNRS UMR 5164, Immuno ConcEpT, Bordeaux University, Bordeaux.

Christian Agard (C)

Department of Internal Medicine, CHU Nantes, Nantes.

Bruno Gombert (B)

Department of Rheumatology, La Rochelle Hospital, La Rochelle.

Mathieu Puyade (M)

Department of Internal Medicine and Infectious Diseases, Poitiers Universitary Hospital, Poitiers.

Aurélie Foucher (A)

Department of Internal Medicine, CHU de La Réunion, Saint Pierre.

Anne-Sophie Alary (AS)

Laboratory of Hematology, Cochin Institute, Paris University, Paris.

François-Xavier Danlos (FX)

Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases.

Alexis Régent (A)

Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases.

Luc Mouthon (L)

Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases.

Loïc Guillevin (L)

Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases.

Maxime Samson (M)

Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France.

Olivier Kosmider (O)

Laboratory of Hematology, Cochin Institute, Paris University, Paris.

Benjamin Terrier (B)

Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH